Latent Style-based Quantum Wasserstein GAN for Drug Design
Julien Baglio 1,2,∗ , Yacine Haddad 3,4,∗ and Richard Polifka 2 · 2026
Read Latent Style-based Quantum Wasserstein GAN for Drug Design by Julien Baglio 1,2,∗ , Yacine Haddad 3,4,∗ and Richard Polifka 2 (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2603-22399.txt.
Introduction
Baglio and co-authors design drugs with a style-based quantum generative network. Classic GANs are hard to train and can collapse to a few outputs. Quantum models may dodge those traps with fewer parameters. Their design encodes noise at each rotation gate of the circuit. A gradient penalty in the loss also fights mode collapse. A variational autoencoder first maps molecules into a latent space for the quantum model. They test the setup on simulators and on IBM quantum hardware.
Catalog record
| CREATOR | Julien Baglio 1,2,∗ , Yacine Haddad 3,4,∗ and Richard Polifka 2 |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86608 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2603.22399
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Latent Style-based Quantum Wasserstein GAN for Drug Design Julien Baglio 1,2,∗ , Yacine Haddad 3,4,∗ and Richard Polifka 2 Abstract 1 The development of new drugs is a tedious, time-consuming, and expensive process, for which the average costs are estimated to be up to around $2.5 billion. The first step in this long process is the design of the new drug, for which de novo drug design, assisted by artificial intelligence, has blossomed in recent years and revolutionized the field. In particular, generative artificial intelligence has delivered promising results in drug discovery and development, reducing costs and the time to solution. However, classical generative models, such as generative adversarial networks (GANs), are difficult to train due to barren plateaus and prone to mode collapse. Quantum computing may be an avenue to overcome these issues and provide models with fewer parameters, thereby enhancing the generalizability of GANs. We propose a new style-based quantum GAN (QGAN) architecture for drug design that implements noise encoding at every rotational gate of the circuit and a gradient penalty in the loss function to mitigate mode collapse. Our pipeline employs a variational autoencoder to represent the molecular structure in a latent space, which is then used as input to our QGAN. Our baseline model runs on up to 15 qubits to validate our architecture on quantum simulators, and a 156-qubit IBM Heron quantum computer in the five-qubit setup is used for inference to investigate the effects of using real quantum hardware on the analysis. We benchmark our results against classical models as provided by the MOSES benchmark suite. \helveticabold 2 Keywords: drug design, smiles, artificial intelligence, latent space, variational auto-encoder, quantum machine learning, quantum generative adversarial networks, superconducting-qubit quantum computer \correspondance \extraAuth † † firstpage: 1 3 Introduction The development of new pharmaceutical drugs is a lengthy, tedious, and expansive process. It takes usually 15 years, and the lower estimate of mean expense is around $1.3 billion [ 1 , 2 , 3 , 4 ] , and can rise up to around $2.5 billion [ 5 , 6 ] . The development cycle consists of the following main stages: target discovery, molecular design, preclinical studies, clinical trials, and finally the regulatory approval to enter the market. In the first two stages, there exist two key strategies for identifying viable drug candidates: either by modifying already existing commercial drugs, for example by performing a virtual screening, or by identifying new relationships between already known molecular structures and the desired activity; or by generating entirely new molecules, also called de-novo drug design. In both methods there are multiple challenges, such as the safety of the candidate molecule, the efficiency, and eventually the ability to manufacture the drug candidate. In this context, the emergence of artificial intelligence (AI) has revolutionized the drug design approach, in particular the advances of generative AI which has been used for computer-assisted drug design in the past decade [ 7 , 8 , 9 ] . Generative Adversarial Networks (GAN) [ 10 ] are prominent AI models applied for drug design [ 11 , 12 ] . A GAN is composed of two neural networks: 1) a generator, which is trained to create new molecular structures from random noise input distribution; 2) a discriminator, which is trained to classify between the generator (fake) output, and the (real) molecular structures contained in the train input dataset. The training scheme is an adversarial game, where the generator aims to fool the discriminator as much as possible while the discriminator aims to distinguish between real data and newly generated fake data, which in turn will help the generator to perform better. While GANs (and more generally AI models for drug design) have blossomed in the past decade, their training can be computationally expensive when their scale is very large, and the associated massive parameter space requires careful optimization [ 11 ] . GANs can suffer from a non convergence of the adversarial training procedure, mode collapse when the generator only generates a sub-sample of the entire diversity of the molecules present in the training set, or falling into a non-robust training pattern with a great sensitivity to the hyperparameters of the models and to the initialization of the model weights. Quantum machine learning aims to provide new avenues to overcome some of these challenges. Quantum generative models [ 13 , 14 , 15 , 16 , 17 ] are generative models relying on the rules of quantum mechanics: Starting from quantum states encoding the problem, subject to the rules of superposition and entanglement, they build up the final probabilistic output distribution using quantum measurements. Using spectral analysis, it has been shown that quantum neural networks probe different frequency modes compared to their classical counterparts, a feature which seems to be linked to higher expressivity of quantum machine learning [ 18 , 19 , 20 , 21 ] . Quantum GANs (QGANs) [ 22 , 23 , 24 , 25 , 26 , 27 ] thus offer new avenues for powerful generative neural networks and have been applied to drug design [ 28 , 29 , 30 , 31 ] . In [ 30 , 31 ] the authors have adopted the Wasserstein distance as the backbone of the loss function (WGAN) [ 32 ] , leading to an improvement over the early QGAN investigations for drug discovery [ 28 , 29 ] . In [ 31 ] this was also supplemented by gradient penalty (WGAN-GP) [ 33 ] to improve trainability. In [ 30 , 31 ] the quantum architecture was a modification of the MolGAN architecture [ 34 ] , the standard in computer-assisted drug design, and the two studies applied their quantum models on dataset of small molecules, QM9 dataset [ 35 ] and PC9 dataset [ 36 ] . In this work we propose two improvements: 1) going beyond small-molecule generation and 2) investigating several modifications over the previous QGAN studies which enable a new state of the art for QGAN in computer-assisted drug design. First, we use the MOSES dataset and benchmark suite [ 37 ] , which is an industry-relevant dataset of SMILES molecules [ 38 ] not restricted to small molecules. In addition, aiming to exploit potential quantum advantages for sampling efficiency and model expressiveness and to address the challenge of mode collapse, we introduce a latent space approach in the quantum computing pipeline, following classical GAN studies for drug design [ 39 ] . The input SMILES molecules of the training dataset are projected into an abstract vector space on which the training is done, before decoding the output back to the practical, physical space. Our last improvement over previous quantum studies is the combination of this latent-space approach with a hybrid style-based quantum GAN [ 40 , 41 ] which uses data re-uploading, where the input noise distribution for the generator is inserted in all layers and not only in the first initial layer of the neural network. The style architecture was introduced for classical GAN in the context of image generation [ 42 ] and the latent style-based QGAN using WGAN-GP has been successfully tested for image generation [ 43 ] but never investigated for drug design.